Polly A. Murphy
Independent DirectorDr. Polly A. Murphy, D.V.M., M.B.A., Ph.D., is Chief Business Officer of Avadel Pharmaceuticals plc from May 2024. Dr. Murphy has Ph.D. in Veterinary Pathology from Iowa State University in 1994. Dr. Murphy serves as an Independent Director of Celcuity Inc. since September 12, 2022. She had been Chief Business Officer of UroGen Pharma Ltd. since August 2020 until May 2024. Dr. Murphy has served as Chief Business Officer at Avadel Pharmaceuticals plc since May 2024. Since September 2008, Dr. Murphy served at Pfizer, Inc., as Vice President and Head of Commercial Development Pfizer Oncology Business Unit from January 2019 to August 2020, Vice President and Head of Global Marketing and Commercial Development Pfizer Oncology Business Unit from June 2017 to December 2018 and as Vice President and Head of Strategy and Business Development for Pfizer China from November 2013 to May 2018, where she was in charge of business and commercial development, as well as strategy and innovation for the company's biopharmaceutical business in China. Prior to Pfizer, Dr. Murphy held senior leadership positions at several pharmaceutical and academic research entities, including The Scripps Research Institute, Salk Institute and Aurora Biosciences. She has many years of business development and commercial strategy experience at leading global pharmaceutical companies, including years in leadership positions with increasing responsibility at Pfizer. While at Pfizer she led business development for Worldwide R&D and the global Specialty Care Business Unit and later Global Marketing and Commercial Development for the Pfizer Oncology Business Unit. Dr. Murphy worked at The Scripps Research Institute as the Senior Vice President, Business and Scientific Services, where she oversaw licensing and scientific operations. Dr. Murphy has biopharmaceutical experience spanning business development, commercial, strategy, operations and R&D. She has been an Independent Director of Atea Pharmaceuticals, Inc. since August 2020. Dr. Murphy received her Doctor of Veterinary Medicine (D.V.M) in 1989 and also Ph.D. in Veterinary Pathology from Iowa State University in 1994 as well as a Master of Business Administration from Nova Southeastern University in 1998.
Positions
- Company NameAtea Pharmaceuticals, Inc.Stock CodeAVIRPositionIndependent DirectorColleagues
- JSJean-Pierre SommadossiFounder, Chairman, CEO & President
- AJAndrea J. CorcoranCFO, Executive VP of Legal & Secretary
- JFJohn F. VavrickaChief Commercial Officer
- JMJanet M. J. HammondChief Development Officer
- MAMaria Arantxa HorgaChief Medical Officer
- FMFranklin M. BergerLead Independent Director
- BGBarbara G. DuncanIndependent Director
- BLBruno LucidiIndependent Director
